Cipla gets USFDA EIR for Indore facility

Mumbai: Pharma major, Cipla, has recently announced that the Company has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Indore plant, indicating the closure of the inspection.

The inspection was conducted from 27th June 2022 to 1st July 2022.

"Further to the intimation dated 4th July 2022, this is to inform you that following the product-specific PreApproval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at the Indore plant from 27th June 2022 to 1st July 2022, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection," the Company stated in a BSE filing,

Medical Dialogues team had earlier reported that the USFDA had issued two observations after a Pre Approval Inspection at the Company's Indore plant.

Read also: Cipla Indore plant gets 2 USFDA observations

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.

Read also: Cipla Cancer drug Lenalidomide bags USFDA okay